aTyr Pharma Inc.
3545 John Hopkins Road, Suite 250
San Diego
California
92121
United States
227 articles with aTyr Pharma Inc.
-
aTyr Pharma to Present at September 2020 Investor Conferences
9/9/2020
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that the company will present at two investor conferences in September.
-
aTyr Pharma to Present at Life Sciences Investor Forum on September 17th
9/2/2020
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17.
-
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial ProgramsCompany to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT
8/13/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update.
-
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in JapanStudy will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan.
8/11/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical
-
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial ResultsManagement to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT
8/6/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020. Conference Call and Webcast Details: Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic: 844-358-9116 Internationa
-
aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II
6/22/2020
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer
-
aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection
6/17/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today highlighted new external research demonstrating the involvement of Neuropilin biology in SARS-CoV-2 infection.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
-
aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory ComplicationsTrial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.
6/15/2020
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that it has dosed the first patient in a Phase 2 study evaluating its lead therapeutic candidate, ATYR1923, in COVID-19 patients with severe respiratory complications.
-
aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
5/20/2020
Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer
-
aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT
5/12/2020
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced first quarter results and provided a corporate update.
-
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial ResultsManagement to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT
5/6/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020. Conference Call and Webcast Details: Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic: 844-358-9116 International: 209-90
-
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
5/5/2020
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds to Neuropilin-2 (NRP2), a unique target expressed on key immune cells in inflammatory conditions SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
-
aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application
4/21/2020
aTyr Pharma, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application to evaluate its lead therapeutic candidate, ATYR1923, in a Phase 2 study in COVID-19 patients with severe respiratory complications..
-
aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update
3/26/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced fourth quarter and full year 2019 results and provided a corporate update.
-
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform
3/24/2020
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program Two-year project will initially focus on development of new bi-specific antibodies targeting NRP2 SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company’s Hong Kong subsidiary, Pangu Bi
-
aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26thManagement to host conference call and webcast at 5:00 pm EST / 2:00 pm PST
3/19/2020
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial results after the market close on Thursday, March 26, 2020.
-
Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific AdvisorDr. Mercurio to advise company on the development of novel antibody therapeutics targeting neuropilin-2 (NRP2) for cancer
3/17/2020
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advisor to the company.